TY - JOUR
T1 - Performance of Novel High-Sensitivity Cardiac Troponin I Assays for 0/1-Hour and 0/2- to 3-Hour Evaluations for Acute Myocardial Infarction
T2 - Results From the HIGH-US Study
AU - Nowak, Richard M.
AU - Christenson, Robert H.
AU - Jacobsen, Gordon
AU - McCord, James
AU - Apple, Fred S.
AU - Singer, Adam J.
AU - Limkakeng, Alexander
AU - Peacock, William F.
AU - deFilippi, Christopher R.
N1 - Funding Information:
Funding and support:By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The HIGH-US study was funded by Siemens Healthcare Diagnostics Inc. Dr. Nowak has received fees from Siemens Healthineers as a consultant for the design and conduct of this trial. He has been or is a consultant for Siemens Healthineers, Roche Diagnostics, Beckman Coulter, Ortho Clinical Diagnostics, and Abbott. Dr. Christenson has received fees from Siemens Healthineers for consultancy work on design and conduct of high-sensitivity cardiac troponin I clinical trials and is a consultant for Siemens Healthineers, Roche Diagnostics, Quidel Diagnostics, and Beckman Coulter. Dr. McCord has received research support from Roche, Siemens Healthineers, Abbott, and Beckman Coulter and has served as a consultant for Roche and Siemens Healthineers. Dr. Apple reports serving on the board of directors for HyTest Ltd and the advisory board for Siemens Healthcare and Instrumentation Laboratory. He reports serving as a consultant for LumiraDx; he has served as a nonsalaried principle investigator through Hennepin Healthcare Research Institute for Abbott Diagnostics, Abbott Point of Care, Roche Diagnostics, Siemens Healthcare, Quidel/Alere, Ortho Clinical Diagnostics, and Beckman Coulter. He reports serving as an associate editor for Clinical Chemistry. Dr. Singer reports serving as a consultant for Jansen, Pfizer, BNS, and AstraZeneca. Dr. Limkakeng reports receiving grant funding from Roche Diagnostics, Abbott Laboratories, Bristol-Myers Squibb, Ischemia Care, LTD, and GE AstraZeneca; and serving as a consultant for BioM?rieux and ZS Pharma. Dr. Peacock reports receiving research grants from Abbott, BrainCheck, ImmunArray, Janssen, Ortho Clinical Diagnostics, Relypsa, and Roche; serving as a consultant for Abbott, AstraZeneca, Bayer, Beckman, Boehringer Ingelheim, Ischemia Care, Dx, ImmunArray, Instrument Labs, Janssen, Nabriva Therapeutics, Ortho Clinical Diagnostics, Relypsa, Roche, Quidel, and Siemens Healthineers; and providing expert testimony for Johnson & Johnson. He also reports stock/ownership interests in AseptiScope Inc, Brainbox Inc, Comprehensive Research Association LLC, Emergencies in Medicine LLC, and Ischemia DC LLC. Dr. deFilippi reports receiving research support from Inova; serving as a consultant for Abbott Diagnostics, Fujirebio, Metabolomics, Ortho Diagnostics, Roche Diagnostics, and Siemens Healthineers; receiving honoraria from WebMD; and receiving royalties from UpToDate.
Funding Information:
Funding and support:By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org ). The HIGH-US study was funded by Siemens Healthcare Diagnostics Inc. Dr. Nowak has received fees from Siemens Healthineers as a consultant for the design and conduct of this trial. He has been or is a consultant for Siemens Healthineers, Roche Diagnostics, Beckman Coulter, Ortho Clinical Diagnostics, and Abbott. Dr. Christenson has received fees from Siemens Healthineers for consultancy work on design and conduct of high-sensitivity cardiac troponin I clinical trials and is a consultant for Siemens Healthineers, Roche Diagnostics, Quidel Diagnostics, and Beckman Coulter. Dr. McCord has received research support from Roche , Siemens Healthineers , Abbott , and Beckman Coulter and has served as a consultant for Roche and Siemens Healthineers. Dr. Apple reports serving on the board of directors for HyTest Ltd and the advisory board for Siemens Healthcare and Instrumentation Laboratory. He reports serving as a consultant for LumiraDx; he has served as a nonsalaried principle investigator through Hennepin Healthcare Research Institute for Abbott Diagnostics, Abbott Point of Care, Roche Diagnostics, Siemens Healthcare, Quidel/Alere, Ortho Clinical Diagnostics, and Beckman Coulter. He reports serving as an associate editor for Clinical Chemistry. Dr. Singer reports serving as a consultant for Jansen, Pfizer, BNS, and AstraZeneca. Dr. Limkakeng reports receiving grant funding from Roche Diagnostics, Abbott Laboratories, Bristol-Myers Squibb , Ischemia Care, LTD, and GE AstraZeneca ; and serving as a consultant for BioMérieux and ZS Pharma. Dr. Peacock reports receiving research grants from Abbott , BrainCheck, ImmunArray, Janssen, Ortho Clinical Diagnostics, Relypsa, and Roche ; serving as a consultant for Abbott, AstraZeneca, Bayer, Beckman, Boehringer Ingelheim, Ischemia Care, Dx, ImmunArray, Instrument Labs, Janssen, Nabriva Therapeutics, Ortho Clinical Diagnostics, Relypsa, Roche, Quidel, and Siemens Healthineers; and providing expert testimony for Johnson & Johnson. He also reports stock/ownership interests in AseptiScope Inc, Brainbox Inc, Comprehensive Research Association LLC, Emergencies in Medicine LLC, and Ischemia DC LLC. Dr. deFilippi reports receiving research support from Inova ; serving as a consultant for Abbott Diagnostics, Fujirebio, Metabolomics, Ortho Diagnostics, Roche Diagnostics, and Siemens Healthineers; receiving honoraria from WebMD; and receiving royalties from UpToDate.
Publisher Copyright:
© 2019 American College of Emergency Physicians
PY - 2020/7
Y1 - 2020/7
N2 - Study objective: We determine the accuracy of high-sensitivity cardiac troponin I (hs-cTnI), European-derived, rapid, acute myocardial infarction, rule-out/rule-in algorithms applied to a US emergency department (ED) population. Methods: Adults presenting to the ED with suspected acute myocardial infarction were included. Plasma samples collected at baseline and between 40 and 90 minutes and 2 and 3 hours later were analyzed in core laboratories using the Siemens Healthineers hs-cTnI assays. Acute myocardial infarction diagnosis was independently adjudicated. The sensitivity, specificity, and negative and positive predictive values for rapid acute myocardial infarction rule-out/rule-in using European algorithms and 30-day outcomes are reported. Results: From 29 US medical centers, 2,113 subjects had complete data for the 0/1-hour algorithm analyses. With the Siemens Atellica Immunoassay hs-cTnI values, 1,065 patients (50.4%) were ruled out, with a negative predictive value of 99.7% and sensitivity of 98.7% (95% confidence interval 99.2% to 99.9% and 96.3% to 99.6%, respectively), whereas 265 patients (12.6%) were ruled in, having a positive predictive value of 69.4% and specificity of 95.7% (95% confidence interval 63.6% to 74.7% and 94.7% to 96.5%, respectively). The remaining 783 patients (37.1%) were classified as having continued evaluations, with an acute myocardial infarction incidence of 5.6% (95% confidence interval 4.2% to 7.5%). The overall 30-day risk of death or postdischarge acute myocardial infarction was very low in the ruled-out patients but was incrementally increased in the other groups (rule-out 0.2%; continued evaluations 2.1%; rule-in 4.8%). Equivalent results were observed in the 0/2- to 3-hour analyses and when both algorithms were applied to the hs-cTnI ADVIA Centaur measurements. Conclusion: The European rapid rule-out/rule-in acute myocardial infarction algorithm hs-cTnI cut points can be harmonized with a demographically and risk-factor diverse US ED population.
AB - Study objective: We determine the accuracy of high-sensitivity cardiac troponin I (hs-cTnI), European-derived, rapid, acute myocardial infarction, rule-out/rule-in algorithms applied to a US emergency department (ED) population. Methods: Adults presenting to the ED with suspected acute myocardial infarction were included. Plasma samples collected at baseline and between 40 and 90 minutes and 2 and 3 hours later were analyzed in core laboratories using the Siemens Healthineers hs-cTnI assays. Acute myocardial infarction diagnosis was independently adjudicated. The sensitivity, specificity, and negative and positive predictive values for rapid acute myocardial infarction rule-out/rule-in using European algorithms and 30-day outcomes are reported. Results: From 29 US medical centers, 2,113 subjects had complete data for the 0/1-hour algorithm analyses. With the Siemens Atellica Immunoassay hs-cTnI values, 1,065 patients (50.4%) were ruled out, with a negative predictive value of 99.7% and sensitivity of 98.7% (95% confidence interval 99.2% to 99.9% and 96.3% to 99.6%, respectively), whereas 265 patients (12.6%) were ruled in, having a positive predictive value of 69.4% and specificity of 95.7% (95% confidence interval 63.6% to 74.7% and 94.7% to 96.5%, respectively). The remaining 783 patients (37.1%) were classified as having continued evaluations, with an acute myocardial infarction incidence of 5.6% (95% confidence interval 4.2% to 7.5%). The overall 30-day risk of death or postdischarge acute myocardial infarction was very low in the ruled-out patients but was incrementally increased in the other groups (rule-out 0.2%; continued evaluations 2.1%; rule-in 4.8%). Equivalent results were observed in the 0/2- to 3-hour analyses and when both algorithms were applied to the hs-cTnI ADVIA Centaur measurements. Conclusion: The European rapid rule-out/rule-in acute myocardial infarction algorithm hs-cTnI cut points can be harmonized with a demographically and risk-factor diverse US ED population.
UR - http://www.scopus.com/inward/record.url?scp=85079175554&partnerID=8YFLogxK
U2 - 10.1016/j.annemergmed.2019.12.008
DO - 10.1016/j.annemergmed.2019.12.008
M3 - Article
C2 - 32046869
AN - SCOPUS:85079175554
SN - 0196-0644
VL - 76
SP - 1
EP - 13
JO - Annals of Emergency Medicine
JF - Annals of Emergency Medicine
IS - 1
ER -